FOXM1 and pancreatic neoplasm: In previous research, TST has been reported to inhibit FOXM1 and the malignant behaviour of a variety of tumours, including colorectal cancer, breast cancer, lung cancer, acute lymphoblastic leukaemia, ovarian cancer, and even pancreatic cancer [10–15].